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40 word summary: Definitions for a four-stage continuum of HIV care were standardised and applied 
to HIV surveillance and national cohort data in 11 European Union countries. These countries are 
nearing the UNAIDS 90-90-90 target, although reducing the proportion undiagnosed remains 
challenging. 
  
  
2 
 
Abstract 
 
Background: UNAIDS has set a 90-90-90 target to curb the HIV epidemic by 2020, but methods used 
to assess whether countries have reached this target are not standardised, hindering comparisons. 
 
Methods: Through a collaboration formed by the European Centre for Disease Prevention and 
Control (ECDC) with European HIV cohorts and surveillance agencies, we constructed a standardised, 
four-stage continuum of HIV care for 11 European Union (EU) countries for 2013. Stages were 
defined as: 1) number of people living with HIV (PLHIV) in the country by end of 2013; 2) proportion 
of stage 1 ever diagnosed; 3) proportion of stage 2 ever initiated ART; and 4) proportion of stage 3 
who became virally-suppressed (≤200 copies/mL). Case surveillance data were used primarily to 
derive stages 1 (using back-calculation models) and 2, and cohort data for stages 3 and 4.  
 
Results: In 2013, 674,500 people in the 11 countries were estimated to be living with HIV, ranging 
from 5,500 to 153,400 in each country. Overall HIV prevalence was 0.22% (range 0.09%-0.36%). 
Overall proportions, of each previous stage, were 84% diagnosed, 84% on ART, and 85% virally-
suppressed (60% of PLHIV). Two countries achieved ≥90% for all stages, and over half had reached 
≥90% for at least one stage. 
 
Conclusions: EU countries are nearing the 90-90-90 target. Reducing the proportion undiagnosed 
remains the greatest barrier to achieving this target, suggesting further efforts are needed to 
improve HIV testing rates. Standardising methods to derive comparable continuums of care remains 
a challenge.  
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Introduction 
 
The HIV continuum of care is a public health monitoring tool to conceptualise the care pathway that 
people living with HIV (PLHIV) progress through: diagnosis of HIV infection, linkage to and retention 
in HIV care, initiation of and adherence to antiretroviral therapy (ART), and suppression of viraemia 
[1]. This concept has increasingly been adopted to evaluate HIV programme performance. Four 
stages of the HIV continuum can also be used to monitor the UNAIDS ‘90-90-90’ target (90% of 
PLHIV diagnosed, 90% of those diagnosed on ART, 90% of those on treatment virally-suppressed), 
which aims to curb the HIV epidemic by 2020 [2]. 
 
However, challenges with data quality, appropriate data sources and the absence of standardised 
definitions have hampered comparisons across countries. An initiative led by the European Centre 
for Disease Prevention and Control (ECDC) in 2014 to monitor the Dublin Declaration on Partnership 
to Fight HIV/AIDS in Europe and Central Asia identified that many European countries lacked data for 
some, or all, continuum stages [3, 4]. This study, as well as a recent systematic review, concluded 
that, although many continuum estimates are being published, their comparability is limited by 
differences in data sources and methods used [3, 5].  
 
Collaborations between public health surveillance and national clinical cohorts, where the latter 
exist, could help address gaps in data availability. The key advantage of using longitudinal clinical 
cohort data lies in their potential to enhance the internal consistency of care continuums by using 
the same group of individuals, defined as ‘denominator-denominator linkage’ [6], to analyse multiple 
stages. While the ideal continuum will maximise the number of stages with denominator-
denominator linkage, additional data from HIV case surveillance systems are necessarily required to 
provide information on the diagnosed population, and as modelling inputs to estimate the total 
number of PLHIV. 
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We, therefore, aimed to construct a four-stage standardised continuum of HIV care for eleven 
European countries using HIV case surveillance and national clinical cohort data. We assess the 
utility of using cohort data and describe the challenges encountered.  
 
Methods 
Selection of countries and cohorts 
HIV cohorts were drawn from EuroCoord (www.EuroCoord.net), a European Union (EU)-funded 
Network of Excellence that includes most European HIV cohorts [7, 8]. Only cohorts considered 
national, i.e. multi-centre and not restricted by risk group, were included. HIV cohorts and 
surveillance agencies in Austria, Belgium, Denmark, France, Germany, Greece, Italy, the Netherlands, 
Spain, Sweden and the United Kingdom (UK) took part (Supplement 1).  
 
Standardised definitions and data sources  
Continuums of HIV care were constructed for each country using national-level HIV case surveillance 
data and HIV clinical cohort data. Four stages of the continuum of HIV care were estimated for 2013, 
the most recent year of data available (Table 1).   
 
Stage 1: Number of PLHIV 
Stage 1 was defined as the estimated total number of PLHIV in each country by the end of 2013. 
Those who had died or out-migrated were excluded where possible. Several countries had no out-
migration data or could only make assumptions about the proportion who out-migrated 
(Supplement 2).  
 
Where feasible, back-calculation models that estimate HIV incidence and the undiagnosed fraction 
from routinely collected HIV case surveillance data were used. For consistency, PLHIV estimates 
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generated using a back-calculation modelling tool developed by the ECDC [9] were prioritised. Five 
countries used the ECDC Modelling Tool ‘incidence method’ [10]. If this was not appropriate, e.g. 
due to incomplete case surveillance data, similar back-calculation methods tailored to countries’ 
own data were used (four countries), either to estimate the total number of PLHIV directly, or to 
estimate the undiagnosed population, combined with surveillance or survey-based estimates of the 
diagnosed population [11-13]. Otherwise, alternative approaches included multi-parameter 
evidence synthesis incorporating case surveillance and prevalence survey data (one country) [14], or 
surveillance/survey-based estimates (one country) (Supplement 2).  
 
Where feasible, 95% confidence intervals were calculated using bootstrapping techniques. Adult 
prevalence was calculated using Eurostat population denominators for 2013 [15], excluding children 
<15 years.  
 
Stage 2: Proportion diagnosed 
Stage 2 was defined as the proportion of all PLHIV, estimated as above, ever diagnosed, excluding 
deaths and out-migrations (Supplement 2).  
 
Ideally, the diagnosed population was derived from cumulative HIV case surveillance data to the end 
of 2013 (three countries). Where this was not feasible, e.g. surveillance systems that started recently 
or changed over time in geographic coverage, alternative approaches were used. These included: 
estimating the diagnosed fraction from the ECDC HIV Modelling Tool (two countries); combining 
estimates of the diagnosed population in care and not in care by triangulating data sources (one 
country) [16]; use of national cohort data, i.e. the number of patients diagnosed and in care, where 
linkage to care is expected to be extremely high (three countries); statistical modelling using recent 
HIV case surveillance data to estimate new HIV diagnoses for all years (one country); or infectious 
disease clinic survey-based estimates (one country) [17].  
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A range of uncertainty was calculated by dividing the number diagnosed by the lower/upper 
confidence limits for the number of PLHIV, to reflect the uncertainty in estimating stage 1. 
 
Stage 3: Proportion on ART 
Stage 3 was defined as the proportion of those diagnosed, as above, who have ever initiated ART, 
regardless of prevailing treatment guidelines, anti-retroviral regimens or number of drugs, 
treatment interruptions or discontinuations. This definition was applied to country-specific cohort 
datasets. Patients known to have died or out-migrated by the end of 2013 were excluded, as were 
patients with unknown year of diagnosis if it was unclear they were diagnosed before the end of 
2013. Those with unknown ART status or unknown year of ART initiation were assumed to be 
untreated by the end of 2013. 
 
Minimum and maximum estimates were calculated based on assumptions about patients lost to 
follow-up (LTFU) to the cohort and whether they were likely to be receiving care in non-cohort 
centres, or lost to care entirely and, therefore, likely not on ART and unsuppressed. For the 
maximum estimate, patients LTFU were excluded, and for the minimum estimate they were included 
and assumed to be untreated, unless their records indicated ART initiation. LTFU was defined as no 
clinic interaction 01/07/2012 - 31/12/2013 and, therefore, no ART or viral load (VL) data. Clinic 
interaction was based on any laboratory measurement, drug start date, or other evidence of an HIV 
clinic visit. The preferred estimate was the mid-point between the minimum and maximum 
estimate. 
 
Stage 4: Proportion virally-suppressed 
Stage 4 was defined as the proportion of those ever on ART, as above, with a VL measurement ≤200 
HIV RNA copies/mL, or below the assay detection limit, at their last visit 01/07/12 - 31/12/13. This VL 
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threshold was chosen to allow for improvements over time in the lower limit of detection of the 
assay. Cohort data were used to calculate minimum and maximum estimates, and the mid-point 
between the two. Patients LTFU (i.e. no recent VL measurements) were excluded for the maximum 
estimate and included for the minimum estimate (assumed to be unsuppressed). Patients with no VL 
measurements 01/07/12 - 31/12/13, but classified as engaged in care based on other laboratory 
measurements, drug start dates or clinic visits, were assumed to be adherent to ART and 
suppressed. 
 
Construction of combined regional estimates  
Country-level results were compiled and combined, and weighted averages calculated for each stage 
to construct a summary continuum for the region based on all 11 countries (Supplement 3). 
Percentages were calculated using the previous stage as the denominator, as well as using a single 
denominator of PLHIV.  
 
Ethics approvals 
All participating clinical cohorts obtained ethics approvals from local ethics committees, national 
data agencies or institutional review boards. Informed consent of patients was sought in accordance 
with national regulations. Surveillance data are collected under the authority of the public health 
agencies that abide with strict confidentiality and privacy data protection laws. 
 
Results 
Continuum of HIV care estimates by country  
National estimates for the total number of PLHIV by the end of 2013 ranged from 5,500 in Denmark 
to 153,400 in France, corresponding to a prevalence of 0.12% and 0.29%, respectively (Table 2). 
Prevalence was lowest in Austria and Sweden (both 0.09%), and highest in Spain (0.36%). 
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There was variation across the countries in the proportions estimated for each stage. In 2013, of all 
PLHIV, the proportions diagnosed ranged from 78% in Greece to 91% in Denmark, with two other 
countries (Italy and Sweden) also reaching ≥90%, and Austria just below this threshold at 88%. Of 
those diagnosed, the proportions on ART range from 76% in Spain to 96% in Belgium. Five other 
countries (Austria, Denmark, France, the Netherlands and Sweden) achieved ≥90% on ART. There 
was less variation between countries in the proportions virally-suppressed. Of those on ART, the 
proportions virally-suppressed were ≥81% in all countries, with the highest proportion estimated at 
93% in both Denmark and Sweden. France and the Netherlands also achieved ≥90% virally-
suppressed. Only two countries, Denmark and Sweden, achieved ≥90% for each of the three 
continuum stages using our standardised definitions. Of the total PLHIV, Denmark and Sweden 
reached ≥73% virally-suppressed, with France and the Netherlands nearing this target, at 72% and 
70% respectively.   
 
Combined estimates for the European region (11 EU countries) 
Overall, 674,500 people were estimated to be living with HIV in the eleven EU countries by the end 
of 2013 (prevalence 0.22%). Overall, the proportions at each stage were: 84% of PLHIV diagnosed 
(79%-90%); 84% of those diagnosed on ART (81%-87%); and 85% of those on ART with viral 
suppression (76%-91%) (Figure 1). Of the total PLHIV, 60% were estimated to be virally-suppressed. 
The greatest drop between successive stages of the continuum was observed between the number 
of PLHIV and the number diagnosed with 16% of undiagnosed individuals falling out of the 
continuum.   
 
Discussion  
Main findings 
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The eleven EU countries included in this study, constituting roughly three quarters of the EU 
population and three quarters of HIV diagnoses in the EU in 2005-2014 [18], are nearing the UNAIDS 
90-90-90 target, well ahead of 2020. Although few countries achieved ≥90% for each stage, based on 
our standardised definitions, over half had reached, or were close to, the target for at least one 
stage. Further improvements are also expected to have occurred since 2013, following recent 
changes in treatment guidelines [19]. However, reducing the undiagnosed proportion remains the 
biggest barrier to achieving this goal, with the largest drop between successive stages of the 
continuum observed at this first stage. To our knowledge, this is the first attempt to standardise 
definitions and derive continuum of care estimates for the EU. Our estimates may differ from 
previously published results and official national statistics due to differences in data sources, 
definitions and time-periods, although these differences are relatively minor [20-25]. 
 
UNAIDS estimates for the number of PLHIV in 2013, derived using Spectrum/EPP software with HIV 
prevalence data and most suitable for countries with generalised epidemics [26], were only reported 
for four of the countries in our study [27]. Our estimates, based primarily on back-calculation 
modelling and routinely-collected HIV case surveillance data, strengthen data availability for this 
stage and provide valuable information for HIV programme monitoring and planning. We observed 
the highest HIV burden in France, Spain, Italy and the UK, accounting for the majority of PLHIV in this 
region, concurring with earlier reports [27]. 
 
Losses from the continuum occurred between all stages, but were greatest between stages 1 and 2. 
Overall, 16% of PLHIV were undiagnosed, indicating further efforts are required to improve HIV 
testing rates, particularly among most at-risk populations. Late presentation remains a major 
concern in Europe, with around half of new diagnoses presenting with CD4<350 cells/mm3 [18, 28]. 
A systematic review published in 2011 suggested that rapid testing and counselling in community 
settings, community-based peer counselling campaigns, and expanding opt-out testing policies may 
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be effective interventions to improve HIV testing rates in men who have sex with men in high-
income countries [29]. Provision of rapid HIV tests in pharmacies [30], and provider-initiated HIV-
testing in general practice or individuals presenting with indicator conditions [31, 32], may offer 
further opportunities to increase testing uptake. Widening legislation for and increasing access to 
self-testing and self-sampling are likely to increase testing, but must be coupled with channels for 
linkage to care [21].  
 
The lowest proportions of diagnosed individuals on ART were estimated in Spain, Italy, Greece, and 
the UK. National treatment guidelines are likely to play a key role here. For example, in 2013, 
treatment guidelines in Greece, Spain and the UK recommended ART initiation in patients with CD4 
counts of ≤350 cells/mm3. The proportion on ART is expected to improve once the recent changes in 
guidelines [19] are implemented. Lack of, or delayed, linkage to care following HIV diagnosis is a 
possible explanation. Although patients in high-income countries are usually linked to care within 
three months of diagnosis, delays among specific sub-groups have been reported [16, 33]. Failure to 
achieve viral suppression after starting ART may reflect poor adherence, treatment interruptions or 
discontinuations, or insufficient time to achieve suppression for those recently initiating ART [16].  
 
Increasing awareness of the continuum of care, e.g. through national treatment and/or service 
delivery guidelines, and providing evidence-based recommendations to improve the testing and care 
environment, may also improve the care continuum [34].  
 
Key challenges 
These results must be interpreted in light of several key methodological challenges encountered. 
Use of the HIV Modelling Tool [9] facilitated the standardisation of estimates for PLHIV, but applying 
the same approach to countries with different HIV surveillance systems was not always possible due 
to insufficient historical case surveillance data availability in some countries. Triangulation of data 
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sources provides one possible solution, for example, summing estimates of the undiagnosed 
population with cohort or survey-based estimates of the diagnosed population in care/ not in care 
[12].  
 
Difficulties capturing out-migration, or linking surveillance or cohort datasets to population 
migration and death registries were additional challenges. Misclassification of vital status or out-
migration will potentially over-estimate the number still alive and living in a country. Few countries 
in our study had access to reliable out-migration data (Supplement 2), with linkage to population 
registries usually precluded by the lack of unique identifiers. Where possible, adjustments were 
made using estimated levels of out-migration. In the long-term, efforts to improve the recording of 
vital status and out-migration in surveillance databases, as well as linkage to registries via unique 
identifiers, are needed. In some cases, lack of reliable in-migration data also complicated modelling 
of HIV incidence and the separating of earlier infections from new infections occurring after arrival 
within the country. 
 
Estimating proportions using cohorts that are not representative of the diagnosed population 
nationally may introduce bias, so efforts are required to understand and correct for this. The cohorts 
in our study were large, including national cohorts with near complete coverage of the diagnosed 
population, and were fairly representative (Supplement 1) [35]. Nevertheless, estimates from 
cohorts with low coverage should be interpreted with caution. Ideally, estimates derived using 
cohort data would be adjusted by calculating and applying weights based on the distribution of 
demographic variables in cohort and surveillance datasets [35].  
 
Patients LTFU in cohort data present another challenge, namely the assumptions that are made 
about whether they are still in care, taking ART and virally-suppressed, or truly lost from care and 
unsuppressed. Assuming all have been lost from care entirely would underestimate retention in care 
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and the proportion suppressed, as suggested by a clinical audit in the UK [36]. Ideally cohorts would 
collect and update data on patients who transfer to other clinics, although this is challenging in 
practice. In the absence of reliable patient transfer data, plausible limits should be calculated based 
on varying assumptions, as we have done, with the true value likely to lie between these limits. 
 
Strengths and limitations 
Collaborations formed between cohort investigators and surveillance agencies facilitated the 
construction of HIV continuums from PLHIV to viral suppression. We attempted to standardise 
methods to enhance comparability between countries, and to generate summary estimates for the 
region. However, complete standardisation was not possible, given the different limitations in data 
availability and quality in each country, as well as inherent differences in cohort inclusion criteria. 
For example, the Italian and Spanish cohorts require participants to be ART-naïve at baseline 
(Supplement 1). Although the use of cohort data improved the internal consistency of the estimates, 
we were unable to link surveillance and cohort datasets in most countries to maximise internal 
consistency. For some countries we were unable to distinguish between those diagnosed and those 
linked to care, i.e. enrolled in a cohort, although linkage to care is expected to be very high.  
 
Additionally, our cross-sectional definitions do not address the timeliness of reaching each stage, or 
time spent at each stage, for example time since starting ART [16]. Using a single VL measurement 
may also over-estimate durable viral suppression [37]. However, they provide a snapshot of the 
continuum in 2013 which is simple to interpret and communicate to policy-makers. Treatment 
discontinuations or interruptions were not accounted for, which may result in over-estimating the 
proportion ‘on ART’. However, a sensitivity analysis conducted for a few countries, restricting the 
definition of ‘on ART’ to a record of ART between 01/07/12 and 30/12/13, made little difference to 
the overall proportions of PLHIV that were virally-suppressed. 
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Finally, our study omitted 17 EU countries, mainly from Eastern and Central Europe as national 
cohort data were lacking and, as such, estimates for the whole EU region may be lower than those 
presented here. 
 
Conclusions 
The 11 EU countries in our study are nearing the UNAIDS 90-90-90 target, with over half having 
achieved ≥90% for one or more stage of the continuum. The main barrier to achieving this goal 
appears to be reducing the proportion undiagnosed. These data provide useful comparisons to 
governments and healthcare planners, but must be interpreted in context of the limitations and key 
challenges above, as well as cohort and country differences. Challenges remain in constructing and 
standardising the continuum of care for all stages. Enhancements to data sources and methods are 
required to derive accurate estimates for national-level continuums of care, to facilitate comparisons 
between countries and to generate regional and global estimates.  
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Figure 1. Continuum of HIV care in 11 EU countries^ for 2013  
 
 
^ Austria, Belgium, Denmark, France, Germany, Greece, Italy, The Netherlands, Spain, Sweden and the United Kingdom 
* Percentages out of the previous stage  
**Percentages out of all PLHIV by end 2013 
 
Weighted averages, accounting for the number of HIV-positive individuals at each stage in each country, were taken across 
all countries for each stage.  
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Table 1. Standardised definitions used to estimate the continuum of care  
 
Stage Definition Data source Analysis and estimation approaches 
i) PLHIV Number of people living with HIV (diagnosed and 
undiagnosed) in each country by end 2013 
HIV case 
surveillance 
data if available, 
or cohort data 
otherwise 
Back-calculation models to estimate HIV incidence and the undiagnosed fraction (ECDC 
HIV Modelling Tool [9], 5 countriesa; other models, 4 countriesb), otherwise Multi-
Parameter Evidence Synthesis (United Kingdom), or other surveillance/survey-based 
estimates (Sweden).  
ii) Diagnosed Proportion of (i) ever diagnosed HIV case 
surveillance 
data if available, 
or cohort data 
otherwise  
Cumulative number of diagnosed by end of 2013, excluding out-migrations and deaths 
before the end of 2013 if feasible (3 countriesc using surveillance data, 3 countriesd using 
national cohort data). Otherwise, the diagnosed population was estimated using: ECDC 
HIV Modelling Tool (Austria, Belgium), statistical modelling (Spain), combining estimates 
of the population in care/ not in care (France), or clinic-based surveys (Italy).  
 
iii) ART Proportion of (ii) who ever initiated ART 
(regardless of treatment guidelines, 
antiretroviral drug regimens or number of drugs, 
treatment interruptions or discontinuations) 
Country-specific 
HIV cohorts 
Descriptive statistics. Patients lost to follow-up to the cohort (ART/viral load status 
unknown) were excluded to give a high estimate, and included (assumed never on ART, 
where ART status unknown) in the low estimate. The preferred estimate was taken as the 
mid-point.  
iv) Virally-
suppressed 
Proportion of (iii) who were virally-suppressed 
(≤200 copies/mL or below the level of detection 
of the assay) at last visit (01/07/12 - 31/12/13) e  
Country-specific 
HIV cohorts 
As above. Patients lost to follow-up to the cohort with no recent viral load measurements 
were assumed to be unsuppressed in the low estimate.  
 
ECDC, European Centre for Disease Prevention and Control  
a Austria, Belgium, Denmark, Greece, the Netherlands  
b France, Germany, Italy, Spain 
c Germany, Greece, United Kingdom 
d Denmark, the Netherlands, Sweden 
e Six months of 2012 were included to allow for delays in updating cohort records.  
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Table 2. Estimates for four stages of the continuum of HIV care for 2013, by country 
 
Country i) PLHIV  
[95% CI] 
HIV 
Prevalence a 
ii) % Diagnosed 
[estimated 
 range] b 
iii) % Ever on ART 
[min, max 
estimate] 
iv) % Suppressed 
[min, max 
estimate] 
% 
Suppressed 
of all PLHIV 
Austria   6500  
[6300-6700] c 
0.09% 88% [86%,91%] 90% [85%,94%]  84% [76%,91%]  66% 
Belgium  18,000  
[17,700-18,300] 
0.19% 84%  [83%,85%] 96% [96%,96%]  82% [77%,87%]  66% 
Denmark  5,500  
[5,000-6,000] d 
0.12% 91% [83%,100%] 94% [93%,94%]  93% [93%,93%]  80% 
France 153,400  
[150,600-155,900]  
0.29% 84% [82%,85%] 93% e 92% e 72% 
Germany  80,000  
[69,000-91,000] 
0.11% 83% [73%,96%] 87% [83%,90%]  81% [69%,92%]  58% 
Greece  14,200  
[13,700-14,600] 
0.15% 78% [76%,81%] 82% [79%,84%]  81% [72%,89%]  52% 
Italy  128,100  
[122,400-133,500] f 
0.25% 90% [86%,94%] 80% [75%,85%]  82% [74%,90%]  59% 
The 
Netherlands  
22,000  
[21,400-22,800] 
0.16% 85% [82%,88%] 91% [90%,92%]  91% [88%,94%]  70% 
Spain  140,700  
[128,200-155,200]  
0.36% 82% [78%,86%] g 76% [73%,78%]  
 
81% [72%,89%] 
 
50% 
Sweden
 
 7,000 h 0.09% 90% h 92% [92%,92%] 93% [93%,93%] 77% 
United 
Kingdom  
99,100  
[93,000-107,400] 
0.19% 81% [75%,87%] i 82% [76%,88%]  82% [70%,94%]  54% 
 
CI confidence interval; PLHIV people living with HIV 
Percentages shown for stages ii) iii) and iv) are out of the previous stage. Percentages in the final column are calculated out 
of the total PLHIV (i).  
Estimates were constructed using standardised methods and may differ from previously published results and official 
national statistics due to differences in data sources, definitions and time-periods. [20-24] 
 
a  Adult HIV prevalence was estimated by dividing the number of PLHIV by Eurostat population denominators for adults 
aged ≥15 years in 2013. 
b Estimated ranges for the % diagnosed were calculated by dividing the number diagnosed by the upper and lower 
confidence limits for stage 1 (PLHIV), to reflect the uncertainty in the estimate for stage 1, unless otherwise indicated. 
c  Estimate for PLHIV generated using Austrian cohort data which covers approx. 76% of people living with HIV in Austria. 
d  Estimated range (CI not available), informed by the ECDC Modelling Tool and triangulation with other estimates. 
e  Minimum estimates are not applicable due to the methodology and data sources used to derive the population in care in 
France. Upper estimates were used to substitute the (missing) minimum estimates when calculating the combined 
estimates for the proportion on ART and proportion virally-suppressed in the 11 EU countries. 
f  Range for PLHIV in Italy calculated using the 95% CI for the undiagnosed estimate and, separately, a range of uncertainty 
for the number diagnosed and lost from care.   
g  95% CI, reflecting the uncertainty in estimating the diagnosed population nationally in Spain, using a statistical model. 
h  Surveillance and survey-based estimate for PLHIV; confidence intervals were therefore not available for the estimate of 
PLHIV, nor was a range available for the diagnosed estimate. However, in Sweden, the number diagnosed is reliably 
estimated from the national cohort and surveillance data, for which there is no under or delayed reporting. Point estimate 
of 7,000 PLHIV used to substitute the (missing) upper and lower limit when calculating the overall range for the % 
diagnosed in the 11 EU countries combined.  
i  Absolute number diagnosed in the UK is reliably derived from national surveillance data. The range presented reflects the 
uncertainty in the estimate for stage 1. 
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Austrian HIV Cohort Study, Austria 
Steering committee members: Ninon Taylor, Maria Geit, Bernhard Haas, Manfred Kanatschnig, 
Armin Rieger, Andrea Steuer, Robert Zangerle 
Coordinating Centre: University Hospital Innsbruck (Robert Zangerle) 
Funding: Austrian Agency for Health and Food Safety (AGES), Hospitals running HIV treatment 
centres, pharmaceutical companies (equal contributions, irrespective of their market shares)  
HIV treatment centres, *site coordinating physicians: (LKH Innsbruck) Martin Gisinger, Maria 
Kitchen, Alexander Plattner, Elisabeth Rieser, Mario Sarcletti*, Robert Zangerle. (LKH Salzburg) 
Alexander Egle, Richard Greil*, Michaela Schachner, Ninon Taylor. (Kepler Universitätsklinikum Med 
Campus III. Linz) Maria Geit*, Angela Öllinger. (AKH Vienna) Regina Aichwalder, Katharina 
Grabmeier-Pfistershammer, Armin Rieger*, Veronique Touzeau. (Otto-Wagner Hospital Vienna) 
Piotr Cichon, Manfred Gartner, Brigitte Schmied, Andrea Steuer*. (Kaiser-Franz-Josef Hospital 
Vienna) Hermann Laferl, Alexander Zoufaly*. (LKH Graz Süd-West) Bernhard Haas*, Andreas Kapper, 
Elmar Wallner. (LKH Klagenfurt) Manfred Kanatschnig*, Georg Schober.  
Virology: Elisabeth Puchhammer-Stöckl (Vienna), Jörg Berg (Kepler Universitäts-klinikum Med 
Campus III. Linz) 
Data management: Heinz Appoyer (IT-related), Gisela Leierer (AHIVCOS), Michaela Rappold 
(AHIVCOS), Stefanie Strickner (AHIVCOS) 
Data safety and protection: Klaus Schindelwig (Innsbruck) 
Scientific advisory board: Bruno Ledergerber (Zurich), Gerd Fätkenheuer (Cologne) 
 
Belgian HIV cohort, Belgium 
The Belgian HIV surveillance including the Belgian HIV cohort is coordinated by the WIV/ISP 
(Scientific Institute of Public Health) and financed by the Belgian National Institute for Sickness and 
Invalidity Insurance (INAMI/RIZIV). 
The WIV-ISP thanks following members of the Belgian Research on AIDS and HIV Consortium 
(BREACH) for providing the data: S. De Wit (ARC CHU Saint-Pierre), M.-L. Delforge (ARL Hôpital 
Erasme), E. Florence (ARC ITG), K. Fransen (ARL ITG), J.-C. Goffard (ARC Hôpital Erasme), M.-P. 
Hayette (ARL CHU Liège), P. Lacor (ARC UZ Brussel), R. Demeester (ARC CHU Charleroi), M. 
Moutschen (ARC CHU Liège), D. Piérard (ARL UZ Brussel), J. Ruelle (ARL UCL), D. Vaira (ARL CHU 
Liège), L. Vandekerckhove (ARC UZ Gent), S. Van den Wijngaert (ARL Hôpital Saint-Pierre), B. 
Vandercam (ARC Cliniques Universitaires Saint-Luc), M. Van Ranst (ARL KUL), E. Van Wijngaerden 
(ARC UZ Leuven), C. Verhofstede (ARL UZ Gent). 
 
Danish HIV Cohort Study, Denmark 
This work was supported by Preben og Anne Simonsens Foundation. 
The Danish HIV Cohort Study includes patients from the Departments of Infectious Diseases at 
Copenhagen University Hospitals, Rigshospitalet (J. Gerstoft, N. Obel) and Hvidovre (G. Kronborg), 
Odense University Hospital (C. Pedersen), Aarhus University Hospitals, Skejby (C.S. Larsen) and 
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Aalborg (G. Pedersen), Herning Hospital (R Mohey), Hillerød Hospital (L. Nielsen), Roskilde Hospital (L 
Weise), Herlev University Hospital (B Kvinesdal) and Kolding Hospital (J. Jensen).  
 
FHDH-ANRS CO4 cohort, France 
The FHDH ANRS CO4 cohort is funded by the ANRS, INSERM and the French Ministry of Health.  
• Scientific committee: S Abgrall, L Bernard, E Billaud, F Boué, L Boyer, A Cabié, F Caby, A 
Canestri, D Costagliola, L Cotte, P De Truchis, X Duval, C Duvivier, P Enel, H Fischer, J Gasnault, C 
Gaud, S Grabar, MA Khuong, O Launay, L Marchand, M Mary-Krause, S Matheron, G Melica-
Grégoire, H Melliez, JL Meynard, M Nacher, J Pavie, L Piroth, I Poizot-Martin, C Pradier, J Reynes, E 
Rouveix, A Simon, L Slama, P Tattevin, H Tissot-Dupont. 
• COREVIH coordinating center: French Ministry of Health (G Astier, J Biga, T Kurth, I Prade), 
Technical Hospitalization Information Agency, ATIH (N Jacquemet). 
• Statistical analysis center: UMRS 1136 INSERM et UPMC (D Costagliola, Principal 
investigator, S Abgrall, S Grabar, M Guiguet, S Lang, L Lièvre, M Mary-Krause, H Roul, H Selinger-
Leneman), INSERM-Transfert (V Potard). 
• COREVIH: Paris area: Corevih Ile de France Centre (Paris-GH Pitié Salpétrière: O Benveniste, 
A Simon, G Breton, C Lupin, E Bourzam; Paris-Hôpital Saint-Antoine: PM Girard, L Fonquernie, N 
Valin, B Lefebvre, M Sebire; Paris-Hôpital Tenon: G Pialoux, MG Lebrette, P Thibaut, A Adda, M 
Hamidi, J Cadranel, A Lavolé, A Parrot), Corevih Ile de France Est (Bobigny-Hôpital Avicenne: O 
Bouchaud, N Vignier, F Méchaï, S Makhloufi, P Honoré; Bondy-Hôpital Jean Verdier; Paris-GH 
Lariboisière-Fernand Widal: JF Bergmann, V Delcey, A Lopes, P Sellier, M Parrinello Paris-Hôpital 
Saint-Louis: E Oksenhendler, L Gerard, JM Molina, W Rozenbaum, B Denis, N De Castro, C Lascoux), 
Corevih Ile de France Nord (Paris-Hôpital Bichat-Claude Bernard: Y Yazdanpanah, S Matheron, S 
Lariven, V Joly, C Rioux; St Denis-Hôpital Delafontaine: MA Khuong-Josses, M Poupard, B Taverne), 
Corevih Ile de France Ouest (Argenteuil-CH Victor Dupouy: L Sutton, V Masse, P Genet, B Wifaq, J 
Gerbe; Boulogne Billancourt-Hôpital Ambroise Paré: E Rouveix, S Greffe, C Dupont, A Freire Maresca, 
E Reimann; Colombes-Hôpital Louis Mourier: M Bloch, F Meier, E Mortier, F Zeng, B Montoya; 
Garches-Hôpital Raymond Poincaré: C Perronne P de Truchis, D Mathez, D Marigot-Outtandy, H 
Berthé; Le Chesnay-Hôpital André Mignot: A Greder Belan, A Therby, C Godin Collet, S Marque 
Juillet, M Ruquet, S Roussin-Bretagne, P Colardelle; Mantes La Jolie-CH François Quesnay: F Granier, 
JJ Laurichesse, V Perronne; Meulan-CHI de Meulan les Mureaux: T Akpan, M Marcou; Nanterre-
Hôpital Max Fourestier: V Daneluzzi, J Gerbe; Poissy-CHI de Poissy: C Veyssier-Belot, H Masson; St 
Germaine en Laye-CHI de St-Germain-en-Laye: Y Welker, P Brazille; Suresnes-Hôpital Foch: JE Kahn, 
D Zucman, C Majerholc, E Fourn, D Bornarel), Corevih Ile de France Sud (Clamart-Hôpital Antoine 
Béclère: F Boué, S Abgrall, V Chambrin, I Kansau, M Raho-Moussa; Créteil-Hôpital Henri Mondor: JD 
Lelievre, G Melica, M Saidani, C Chesnel, C Dumont; Kremlin Bicêtre-Hôpital de Bicêtre: D Vittecoq, O 
Derradji, C Bolliot, C Goujard, E Teicher, J Gasnault, M Mole, K Bourdic; Paris-GH Tarnier-Cochin: D 
Salmon, C Le Jeunne, O Launay, P Guet, MP Pietri, E Pannier Metzger, V Marcou, P Loulergue, N 
Dupin, JP Morini, J Deleuze, P Gerhardt, J Chanal; Paris-Hôpital Européen Georges Pompidou: L 
Weiss, J Pavie, Ml Lucas, C Jung, M Ptak; Paris-Hôpital Hôtel Dieu: JP Viard, J Ghosn, P Gazalet, A 
Cros, A Maignan; Paris-Hôpital Necker adultes: C Duvivier, O Lortholary, C Rouzaud, F Touam, K 
Benhadj; Paris-CMIP Pasteur: PH Consigny, P Bossi, A Gergely, G Cessot, F Durand). 
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Outside Paris area: Corevih Alsace (CH de Mulhouse: G Beck-Wirth, C Michel, M Benomar; CHRU de 
Strasbourg: D Rey, M Partisani, C Cheneau, ML Batard, P Fischer), Corevih de l’Arc Alpin (CHU de 
Grenoble: P Leclercq, M Blanc, P Morand, O Epaulard, A Signori-Schmuck), Corevih Auvergne-Loire 
(CHU de Clermont-Ferrand: H Laurichesse, C Jacomet, M Vidal, D Coban, S Casanova; CHRU de Saint-
Etienne: A Fresard, C Guglielminotti, E Botelho-Nevers, A Brunon-Gagneux, V Ronat); Corevih Basse-
Normandie (CHRU de Caen: R Verdon, S Dargère, E Haustraete, P Féret, P Goubin), Corevih 
Bourgogne (CHRU de Dijon: P Chavanet, A Fillion, L Piroth, D Croisier, S Gohier), Corevih Bretagne 
(CHU de Rennes: C Arvieux, F Souala, JM Chapplain, M Ratajczak, J Rohan), Corevih Centre Poitou-
Charentes (CHRU de Tours), Corevih Franche-Comté (CH de Belfort: JP Faller, O Ruyer, V Gendrin, L 
Toko; CHRU de Besançon: C Chirouze, L Hustache-Mathieu, JF Faucher, A Proust, N Magy-Bertrand, H 
Gil, N Méaux-Ruault); Corevih Haute-Normandie (CHRU de Rouen), Corevih Languedoc-Roussillon 
(CHU de Montpellier; CHU de Nîmes: A Sotto, I Rouanet, JM Mauboussin, R Doncesco, G Jacques), 
Corevih Lorraine Champagne Ardennes (Nancy-Hôpital de Brabois: T May, C Rabaud, M Andre, M 
Delestan, MP Bouillon; CHRU de Reims: F Bani-Sadr, C Rouger, JL Berger, Y Nguyen), Corevih de Midi-
Pyrénées Limousin (Toulouse CHU Purpan: B Marchou, P Delobel, G Martin Blondel, L Cuzin, N 
Biezunski, L Alric, D Bonnet, M Guivarch, A Palacin, V Payssan), Corevih Nord-Pas de Calais (CH de 
Tourcoing: H Melliez, F Ajana, A Meybeck, N Viget), Corevih PACA Est (Nice Hôpital Archet 1: C 
Pradier, P Pugliese, PM Roger, E Rosenthal, J Durant, E Cua, A Naqvi, I Perbost, K Risso; CH Antibes-
Juan les Pins: D Quinsat; CHI de Fréjus/St Raphaël: P Del Giudice; CH de Grasse: PY Dides), Corevih 
PACA Ouest (Marseille-Hôpital de la Conception: P Enel, R Sambuc, MS Antolini-Bouvenot, P Druart, 
L Meddeb, I Ravaux, A Menard, C Tomei, C Dhiver, H Tissot-Dupont; Marseille-Hôpital Nord: J 
Moreau, S Mokhtari, MJ Soavi, V Thomas; Marseille-Hôpital Sainte-Marguerite: I Poizot-Martin, S 
Bregigeon, O Faucher, V Obry-Roguet, AS Ritleng, N Petit; Marseille-Centre pénitentiaire des 
Baumettes: C Bartoli, JM Ruiz, D Blanc; CH d’Aix-En-Provence: T Allegre, M Sordage, JM Riou, C 
Faudon; CH d’Avignon: B Slama, H Zerazhi, O Boulat, S Chebrek, M Beyrne; CH de Digne Les Bains: P 
Granet Brunello; CH de Gap: L Pellissier, D Bonnabel; CH de Martigues: R Cohen Valensi, B Mouchet, 
G Mboungou; CHI de Toulon: A Lafeuillade, E Hope-Rapp, G Hittinger, G Philip, V Lambry), Corevih 
Pays de la Loire (CHU de Nantes: F Raffi, C Allavena, E Billaud, N Hall, V Reliquet), Corevih de la Vallée 
du Rhône (Lyon-Hôpital de la Croix-Rousse: C Chidiac, L Cotte, T Ferry, T Perpoint, P Miailhes; Lyon-
Hôpital Edouard Herriot: A Boibieux, JM Livrozet, D Makhloufi, F Brunel, P Chiarello). 
Overseas: Corevih Guadeloupe (CHU de Pointe-à-Pitre: B Hoen, I Lamaury, I Fabre, K Samar, E 
Duvallon; CH Saint-Martin: C Clavel, S Stegmann, V Walter), Corevih Guyane (CH de Cayenne: M 
Nacher, L Adriouch, F Huber, V Vanticlke, P Couppié), Corevih Martinique (CHU de Fort-de-France: A 
Cabié, S Abel, S Pierre-François), Corevih de La Réunion (St Denis-CHU Félix Guyon: C Gaud, C Ricaud, 
R Rodet, G Wartel, C Sautron; St Pierre-GH Sud Réunion: P Poubeau, G Borgherini, G Camuset). 
 
ClinSurv HIV, Germany 
The clinical surveillance of HIV, ClinSurv HIV, is funded by the Robert Koch Institute, which is the 
German Public Health Institute. 
Berlin: PD Dr K. Arastéh, S. Kowohl  Vivantes (Auguste-Viktoria-Clinic); Dr D. Schürmann, M. Warncke  
Charité, University Medicine Berlin; Bonn: Prof. Dr J. Rockstroh, Dr J. Wasmuth, S. Hass University 
Medical Centre Bonn; Duesseldorf: PD Dr. B.O. Jensen, C. Feind University Medical Centre 
Düsseldorf; Essen: Dr S. Esser, P. Schenk-Westkamp University Clinic Essen; Frankfurt: A. Haberl, C. 
Stephan HIV Center J.W.Goethe-University Frankfurt; Hamburg: Prof. Dr A. Plettenberg, F. 
Kuhlendahl  ifi (Institute for Interdisciplinary Medicine); Drs. A. Adam/ L. Weitner/ K. Schewe, H. 
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Goey, Drs. S. Fenske/ T. Buhk/ Prof. HJ. Stellbrink/ PD C. Hoffmann/ S Hansen at ICH (Infectious 
Diseases Centre) Study Centre Hamburg Hamburg; PD Dr. O Degen, M. Heuer at University Medical 
Centre Hamburg-Eppendorf; Hannover: Prof. Dr M. Stoll, S. Gerschmann at Medical University 
Hannover; Kiel: Prof. Dr H. Horst, S. Trautmann at University Clinic Schleswig-Holstein; Cologne: Prof 
Dr G. Fätkenheuer, D. Gillor at University Medical Centre Cologne; Munich: Prof Dr J. Bogner, B. 
Sonntag at University Hospital Munich; Regensburg: Prof Dr B. Salzberger at University Medical 
Centre Regensburg; Rostock: Dr C. Fritzsche at University Clinic Rostock. 
 
AMACS, Greece  
The AMACS is a collaborative, open, ongoing, population-based cohort study started in 1996, initially 
supported financially by the Hellenic Center for Infectious Diseases Control (HCIDC). 
Steering Committee: Antoniadou A., Chrysos G., Daikos G., Gargalianos-Kakolyris P., Gogos HA., 
Katsarou O., Lazanas M., Metallidis S., Panagopoulos P., Panos G., Paparizos V., Paraskevis D., 
Sambatakou H., Sipsas N., Skoutelis A., Touloumi G. (Chair). Coordinating Center: Department of 
Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Greece (Touloumi 
G., Pantazis N., Vourli G., Souliou T., Gioukari V.) 
Participating Centers: 4th Dept of Internal Medicine, Athens Medical School, Attikon University  
Hospital (Antoniadou A, Papadopoulos A, Petrikkos G); Infectious Disease Unit, “Tzaneio” General 
Hospital of Pireaus (Chrysos G, Paraskeva D, Hatziastros P); 1st Dept of Propedeutic Medicine, 
Athens University, Medical School “Laikon” General Hopsital (Daikos G, Psichogiou M); 1st Dept of 
Medicine, Infectious Diseases Unit, "G. Gennimatas" Athens General Hospital  (Gargalianos-Kakolyris 
P, Xylomenos G); 1st Dept of Internal Medicine, Infectious Diseases Section, Patras University 
Hospital (Gogos HA, Marangos MN, Panos G); Haemophilia Centre, 2nd Blood Transfusion Centre, 
“Laikon” Athens General Hospital (Katsarou O, Kouramba A, Ioannidou P); AIDS Unit, Dept of 
Pathophysiology, “Laikon” Athens General Hospital and Athens University, Medical School (Sipsas 
NV, Kontos A); Infectious Diseases Unit, Red Cross General Hospital of Athens (Lazanas M, Chini M, 
Tsogas N); 1st Dept of Internal Medicine, Infectious Diseases Devision, AHEPA University Hospital, 
Aristotle University HIV Unit (Metallidis S, Tsachouridou O, Skoura L); 2nd Internal Medicine Clinic, 
1st IKA (Panos G, Haratsis G); AIDS Unit, Clinic of Venereologic & Dermatologic Diseases, Athens 
University, Medical School, Syngros Hospital (Paparizos V, Leuow K, Kourkounti S); HIV Unit, 2nd Dpt. 
of Internal Medicine, Athens University, Medical School, Hippokration General Hospital (Sambatakou 
H, Mariolis I); Infectious Diseases & HIV Division, Dept of Internal Medicine, Evaggelismos Athens 
General Hospital (Skoutelis A, Papastamopoulos V); Infectious Diseases Unit, University General 
Hospital of Alexandroupolis, Democritus University of Thrace (Panagopoulos P, Ganitis A).    
 
ICoNA, Italy 
BOARD OF DIRECTORS 
A d’Arminio Monforte (President), M Andreoni, A Antinori, A Castagna, F Castelli, R Cauda, G Di Perri, 
M Galli, R Iardino, G Ippolito, A Lazzarin, G Marchetti, CF Perno, F von Schloesser, P Viale 
SCIENTIFIC SECRETARY 
A d’Arminio Monforte, A Antinori, A Castagna, F Ceccherini-Silberstein, A Cozzi-Lepri, E Girardi, S Lo 
Caputo, C Mussini, M Puoti 
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STEERING COMMITTEE  
M Andreoni, A Ammassari, A Antinori, C Balotta, A Bandera, P Bonfanti, S Bonora, M Borderi, A 
Calcagno, L Calza, MR Capobianchi, A Castagna, F Ceccherini-Silberstein, A Cingolani, P Cinque, A 
Cozzi-Lepri, A d’Arminio Monforte, A De Luca, A Di Biagio, E Girardi, N Gianotti, A Gori, G Guaraldi, G 
Lapadula, M Lichtner, S Lo Caputo, G Madeddu, F Maggiolo, G Marchetti, S Marcotullio, L Monno, C 
Mussini, S Nozza, M Puoti, E Quiros Roldan, R Rossotti, S Rusconi, MM Santoro, A Saracino, M 
Zaccarelli. 
STATISTICAL AND MONITORING TEAM 
A Cozzi-Lepri, I Fanti, L Galli, P Lorenzini, A Rodano, M Shanyinde, A Tavelli 
BIOLOGICAL BANK INMI  
F Carletti, S Carrara, A Di Caro, S Graziano, F Petrone, G Prota, S Quartu, S Truffa 
PARTICIPATING PHYSICIANS AND CENTERS 
Italy A Giacometti, A Costantini, C Valeriani (Ancona); G Angarano, L Monno, C Santoro (Bari); F  
Maggiolo, C Suardi (Bergamo); P Viale, V Donati, G Verucchi (Bologna); F Castelli, E Quiros Roldan, C 
Minardi (Brescia); T Quirino, C Abeli (Busto Arsizio); PE  Manconi, P Piano (Cagliari); B Cacopardo, B 
Celesia (Catania);  J Vecchiet, K Falasca (Chieti); L Sighinolfi, D Segala (Ferrara); F Mazzotta, F Vichi 
(Firenze); G Cassola, C Viscoli, A Alessandrini, N Bobbio, G Mazzarello (Genova); C Mastroianni, V 
Belvisi (Latina); P Bonfanti, I Caramma (Lecco); A Chiodera, AP Castelli (Macerata); M Galli, A 
Lazzarin, G Rizzardini, M Puoti, A d’Arminio Monforte, AL Ridolfo, R Piolini, A Castagna, S Salpietro, L 
Carenzi, MC Moioli, C Tincati, G Marchetti (Milano); C Mussini, C Puzzolante (Modena); A Gori, G 
Lapadula (Monza); N Abrescia, A Chirianni, G Borgia, F Di Martino, L Maddaloni, I Gentile, R Orlando 
(Napoli); F Baldelli, D Francisci (Perugia);  G  Parruti, T Ursini (Pescara); G Magnani, MA Ursitti 
(Reggio Emilia); R Cauda, M Andreoni, A Antinori, V Vullo, A Cristaudo, A Cingolani, G Baldin, S 
Cicalini, L Gallo, E Nicastri, R Acinapura, M Capozzi, R Libertone, S Savinelli, A Latini, G Iaiani, L 
Fontanelli Sulekova (Roma); M Cecchetto, F Viviani (Rovigo); MS Mura, G Madeddu (Sassari); A De 
Luca, B Rossetti (Siena);  P Caramello, G Di Perri, GC Orofino, S Bonora, M Sciandra (Torino); M 
Bassetti, A Londero (Udine); G Pellizzer, V Manfrin (Vicenza). 
 
ATHENA, the Netherlands 
The ATHENA database is maintained by Stichting HIV Monitoring and supported by a grant from the 
Dutch Ministry of Health, Welfare and Sport through the Centre for Infectious Disease Control of the 
National Institute for Public Health and the Environment.  
CLINICAL CENTRES 
* denotes site coordinating physician 
Academic Medical Centre of the University of Amsterdam: HIV treating physicians: J.M. Prins*, T.W. 
Kuijpers, H.J. Scherpbier, J.T.M. van der Meer, F.W.M.N. Wit, M.H. Godfried, P. Reiss, T. van der Poll, 
F.J.B. Nellen, S.E. Geerlings, M. van Vugt, D. Pajkrt, W.J. Wiersinga, M. van der Valk, A. Goorhuis, J.W. 
Hovius. HIV nurse consultants: M.A.H. Bijsterveld, J. van Eden, A.M.H. van Hes, M. Mutschelknauss, 
H.E. Nobel, F.J.J. Pijnappel,  A.M. Weijsenfeld. HIV clinical virologists/chemists: S. Jurriaans, N.K.T. 
Back, H.L. Zaaijer, B. Berkhout, M.T.E. Cornelissen, C.J. Schinkel, X.V. Thomas. Admiraal De Ruyter 
Ziekenhuis, Goes: HIV treating physicians: M. van den Berge, A. Stegeman. HIV nurse consultants: S. 
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Baas, L. Hage de Looff. HIV clinical virologists/chemists: B Wintermans, J Veenemans. Catharina 
Ziekenhuis, Eindhoven: HIV treating physicians: M.J.H. Pronk*, H.S.M. Ammerlaan. HIV nurse 
consultants: E.S. de Munnik, E. van Beek. HIV clinical virologists/chemists: A.R. Jansz, J. Tjhie, M.C.A. 
Wegdam, B. Deiman, V. Scharnhorst. Elisabeth-TweeSteden Ziekenhuis, Tilburg: HIV treating 
physicians: M.E.E. van Kasteren*, A.E. Brouwer. HIV nurse consultants: R. van Erve, B.A.F.M. de 
Kruijf-van de Wiel, S.Keelan-Pfaf, B. van der Ven. Data collection: B.A.F.M. de Kruijf-van de Wiel, B. 
van der Ven.  HIV clinical virologists/chemists: A.G.M. Buiting, P.J. Kabel, D.Versteeg. Emma 
Kinderziekenhuis: HIV nurse consultants: A. van der Plas, A.M. Weijsenfeld. Erasmus MC, Rotterdam: 
HIV treating physicians: M.E. van der Ende*, H.I. Bax, E.C.M. van Gorp, J.L. Nouwen, B.J.A. Rijnders, 
C.A.M. Schurink, A. Verbon, T.E.M.S. de Vries-Sluijs. HIV nurse consultants: N. Bassant, J.E.A. van 
Beek, M. Vriesde, L.M. van Zonneveld. Data collection: H.J. van den Berg-Cameron, F.B. Bruinsma-
Broekman, J. de Groot, M. de Zeeuw-de Man. HIV clinical virologists/chemists: C.A.B. Boucher, M.P.G 
Koopmans, J.J.A van Kampen, S.D. Pas. Erasmus MC–Sophia, Rotterdam: HIV treating physicians: 
G.J.A. Driessen, A.M.C. van Rossum. HIV nurse consultants: L.C. van der Knaap, E. Visser. 
Flevoziekenhuis, Almere: HIV treating physicians: J. Branger*, A. Rijkeboer-Mes. HIV nurse 
consultant and data collection: C.J.H.M. Duijf-van de Ven. HagaZiekenhuis, Den Haag: HIV treating 
physicians: E.F. Schippers*, C. van Nieuwkoop. HIV nurse consultants: J.M. van IJperen, J. Geilings. 
Data collection: G. van der Hut. HIV clinical virologist/chemist: P.F.H. Franck. HIV Focus Centrum (DC 
Klinieken): HIV treating physicians: A. van Eeden*. HIV nurse consultants: W. Brokking, M. Groot, 
L.J.M. Elsenburg. HIV clinical virologists/chemists: M. Damen, I.S. Kwa. Isala, Zwolle: HIV treating 
physicians: P.H.P. Groeneveld*, J.W. Bouwhuis. HIV nurse consultants: J.F. van den Berg, A.G.W. van 
Hulzen. Data collection: G.L. van der Bliek, P.C.J. Bor. HIV clinical virologists/chemists: P. 
Bloembergen, M.J.H.M. Wolfhagen, G.J.H.M. Ruijs. Leids Universitair Medisch Centrum, Leiden: HIV 
treating physicians: F.P. Kroon*, M.G.J. de Boer, H. Jolink, A.M. Vollaard. HIV nurse consultants: W. 
Dorama, N. van Holten. HIV clinical virologists/chemists: E.C.J. Claas, E. Wessels. Maasstad 
Ziekenhuis, Rotterdam: HIV treating physicians: J.G. den Hollander*, K. Pogany, A. Roukens. HIV 
nurse consultants: M. Kastelijns, J.V. Smit, E. Smit, D. Struik-Kalkman, C. Tearno. Data collection: M. 
Bezemer, T. van Niekerk. HIV clinical virologists/chemists: O. Pontesilli. Maastricht UMC+, 
Maastricht: HIV treating physicians: S.H. Lowe*, A.M.L. Oude Lashof, D. Posthouwer. HIV nurse 
consultants: R.P. Ackens, J. Schippers, R. Vergoossen. Data collection: B. Weijenberg-Maes. HIV 
clinical virologists/chemists: I.H.M. van Loo, T.R.A. Havenith. MCH-Bronovo, Den Haag: HIV treating 
physicians: E.M.S. Leyten*, L.B.S. Gelinck. HIV nurse consultants: A.Y. van Hartingsveld, C. Meerkerk, 
G.S. Wildenbeest. HIV clinical virologists/chemists: J.A.E.M. Mutsaers, S.Q. van Veen. MC Slotervaart, 
Amsterdam: HIV treating physicians: J.W. Mulder*, S.M.E. Vrouenraets, F.N. Lauw. HIV nurse 
consultants: M.C. van Broekhuizen, H. Paap, D.J. Vlasblom. HIV clinical virologists/chemists: P.H.M. 
Smits. MC Zuiderzee, Lelystad: HIV treating physicians: S. Weijer*, R. El Moussaoui. HIV nurse 
consultant: A.S. Bosma. Medisch Centrum Leeuwarden, Leeuwarden: HIV treating physicians: 
M.G.A.van Vonderen*, D.P.F. van Houte, L.M. Kampschreur. HIV nurse consultants: K. Dijkstra, S. 
Faber. HIV clinical virologists/chemists: J Weel. Medisch Spectrum Twente, Enschede: HIV treating 
physicians: G.J. Kootstra*, C.E. Delsing. HIV nurse consultants: M. van der Burg-van de Plas, H. Heins. 
Data collection: E. Lucas. Noordwest Ziekenhuisgroep, Alkmaar: HIV treating physicians: W. 
Kortmann*, G. van Twillert*, J.W.T. Cohen Stuart, B.M.W. Diederen, R. Renckens. HIV nurse 
consultant and data collection: D. Ruiter-Pronk, F.A. van Truijen-Oud. HIV clinical 
virologists/chemists: W. A. van der Reijden, R. Jansen. OLVG, Amsterdam: HIV treating physicians: K. 
Brinkman*, G.E.L. van den Berk, W.L. Blok, P.H.J. Frissen, K.D. Lettinga W.E.M. Schouten, J. Veenstra. 
HIV nurse consultants: C.J. Brouwer, G.F. Geerders, K. Hoeksema, M.J. Kleene, I.B. van der Meché, 
M. Spelbrink, H. Sulman, A.J.M. Toonen, S. Wijnands. HIV clinical virologists: M. Damen, D. Kwa. Data 
collection: E. Witte. Radboudumc, Nijmegen: HIV treating physicians: R. van Crevel*, M. Keuter, 
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A.J.A.M. van der Ven, H.J.M. ter Hofstede, A.S.M. Dofferhoff. HIV nurse consultants: M. Albers, K.J.T. 
Grintjes-Huisman, M. Marneef, A. Hairwassers. HIV clinical virologists/chemists: J. Rahamat-
Langendoen. HIV clinical pharmacology consultant: D. Burger. Rijnstate, Arnhem: HIV treating 
physicians: E.H. Gisolf*, R.J. Hassing, M. Claassen. HIV nurse consultants: G. ter Beest, P.H.M. van 
Bentum, N. Langebeek. HIV clinical virologists/chemists: R. Tiemessen, C.M.A. Swanink. Spaarne 
Gasthuis, Haarlem: HIV treating physicians: S.F.L. van Lelyveld*, R. Soetekouw. HIV nurse 
consultants: L.M.M. van der Prijt, J. van der Swaluw. Data collection: N. Bermon. HIV clinical 
virologists/chemists: W.A. van der Reijden, R. Jansen, B.L. Herpers, D.Veenendaal. Medisch Centrum 
Jan van Goyen, Amsterdam: HIV treating physicians: D.W.M. Verhagen. HIV nurse consultants: M. 
van Wijk. Universitair Medisch Centrum Groningen, Groningen: HIV treating physicians: W.F.W. 
Bierman*, M. Bakker, J. Kleinnijenhuis, E. Kloeze, H. Scholvinck, Y. Stienstra, C.L. Vermont, K.R. 
Wilting. HIV nurse consultants: A. Boonstra, H. de Groot-de Jonge, P.A. van der Meulen, D.A. de 
Weerd. HIV clinical virologists/chemists: H.G.M. Niesters, C.C. van Leer-Buter, M. Knoester. 
Universitair Medisch Centrum Utrecht, Utrecht: HIV treating physicians: A.I.M. Hoepelman*, J.E. 
Arends, R.E. Barth, A.H.W. Bruns, P.M. Ellerbroek, T. Mudrikova, J.J. Oosterheert, E.M. Schadd, 
M.W.M. Wassenberg, M.A.D. van Zoelen. HIV nurse consultants: K. Aarsman, D.H.M. van Elst-
Laurijssen, E.E.B. van Oers-Hazelzet. Data collection: M. van Berkel. HIV clinical virologists/chemists: 
R. Schuurman, F. Verduyn-Lunel, A.M.J. Wensing. VUmc, Amsterdam: HIV treating physicians: E.J.G. 
Peters*, M.A. van Agtmael, M. Bomers, J. de Vocht. HIV nurse consultants: M. Heitmuller, L.M. Laan. 
HIV clinical virologists/chemists: C.W. Ang, R. van Houdt, A.M. Pettersson, C.M.J.E. Vandenbroucke-
Grauls. Wilhelmina Kinderziekenhuis, UMCU, Utrecht: HIV treating physicians: S.P.M. Geelen, T.F.W. 
Wolfs, L.J. Bont. HIV nurse consultants: N. Nauta.  
COORDINATING CENTRE  
Director: P. Reiss. Data analysis: D.O. Bezemer, A.I. van Sighem, C. Smit, F.W.M.N. Wit, T.S. Boender. 
Data management and quality control: S. Zaheri, M. Hillebregt, A. de Jong. Data monitoring: D. 
Bergsma, A. de Lang, S. Grivell, A. Jansen, M.J. Rademaker, M. Raethke, R. Meijering, S. Schnörr. Data 
collection: L. de Groot, M. van den Akker, Y. Bakker, E. Claessen, A. El Berkaoui, J. Koops, E. Kruijne, 
C. Lodewijk, L. Munjishvili, B. Peeck, C. Ree, R. Regtop, Y. Ruijs, T. Rutkens, L. van de Sande, M. 
Schoorl, A. Timmerman, E. Tuijn, L. Veenenberg, S. van der Vliet, A. Wisse, T. Woudstra. Patient 
registration: B. Tuk. 
 
CoRIS, Spain 
This work was supported by the Spanish Network of HIV/AIDS (RD12/0017/0018) and CIBER 
Epidemiología y Salud Pública (CIBERESP), Spain. J. del Amo, V. Hernando, A. Diaz: “This article 
presents independent results and research. The views expressed are those of the authors and not 
necessarily those of the Instituto de Salud Carlos III”. 
Centers and investigators involved in CoRIS: Executive committee: Santiago Moreno, Julia del Amo, 
David Dalmau, Maria Luisa Navarro, Maria Isabel González, Jose Luis Blanco, Federico Garcia, Rafael 
Rubio, Jose Antonio Iribarren, Félix Gutiérrez, Francesc Vidal, Juan Berenguer, Juan González. 
Fieldwork, data management and analysis: Paz Sobrino, Victoria Hernando, Belén Alejos, Débora 
Álvarez, Inma Jarrín, Cristina Moreno. BioBanK HIV: M Ángeles Muñoz-Fernández, Isabel García-
Merino, Coral Gómez Rico, Jorge Gallego de la Fuente y Almudena García Torre. Participating 
centres: Hospital General Universitario de Alicante (Alicante): Joaquín Portilla, Esperanza Merino, 
Sergio Reus, Vicente Boix, Livia Giner, Carmen Gadea, Irene Portilla, Maria Pampliega, Marcos Díez, 
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Juan Carlos Rodríguez, Jose Sánchez-Payá. Hospital Universitari de Bellvitge (Hospitalet de 
Llobregat): Daniel Podzamczer, Elena Ferrerm Arkaitz Imaz, Evan Van Den Eyncle, Silvana Di Yacovo, 
Maria Sumoy. Hospital Universitario de Canarias (Santa Cruz de Tenerife): Juan Luis Gómez, 
Jehovana Hernández,  María Remedios Alemán, María del Mar Alonso, María Inmaculada 
Hernández, Felicitas Díaz-Flores, Dácil García, Ricardo Pelazas.  Hospital Universitario Central de 
Asturias (Oviedo): Victor Asensi, Eulalia Valle, José Antonio Cartón. Hospital Clínico San Carlos 
(Madrid): Vicente Estrada Pérez, Maria Jesus Téllez Molina, Jorge Vergas García, Elisa Pérez-Cecila 
Carrera. Hospital Doce de Octubre (Madrid): Rafael Rubio, Federico Pulido, Otilia Bisbal, Mariano 
Matarranz, Maria Lagarde, Rafael Rubio-Martín, Asunción Hernando, Laura Bermejo y Lourdes 
Dominguez. Hospital Universitario Donostia (San Sebastián): José Antonio Iribarren, Julio 
Arrizabalaga, María José Aramburu, Xabier Camino, Francisco Rodríguez-Arrondo, Miguel Ángel von 
Wichmann, Lidia Pascual Tomé, Miguel Ángel Goenaga, Mª Jesús Bustinduy, Harkaitz Azkune 
Galparsoro. Maialen Ibarguren, Mirian Aguado, Maitane Umerez. Hospital General Universitario de 
Elche (Elche): Félix Gutiérrez, Mar Masiá, Cristina López, Sergio Padilla, Andrés Navarro, Fernando 
Montolio, Catalina Robledano, Joan Gregori Colomé, Araceli Adsuar, Rafael Pascual, Federico Carlos, 
Maravillas Martinez, Jara Llenas García, Marta Fernández, Elena García. Hospital Germans Trías i 
Pujol (Badalona): Roberto Muga, Jordi Tor, Arantza Sanvisens. Hospital General Universitario 
Gregorio Marañón (Madrid): Juan Berenguer, Juan Carlos López Bernaldo de Quirós, Pilar Miralles, 
Isabel Gutiérrez, Margarita Ramírez, Belén Padilla, Paloma Gijón, Ana Carrero, Teresa Aldamiz-
Echevarría, Francisco Tejerina, Francisco Jose Parras, Pascual Balsalobre, Cristina Diez. Hospital 
Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili  (Tarragona): Francesc Vidal, 
Joaquín Peraire, Consuelo Viladés, Sergio Veloso, Montserrat Vargas, Miguel López-Dupla, 
Montserrat Olona, Alba Aguilar, Joan Josep Sirvent, Verónica Alba, Olga Calavia . Hospital 
Universitario La Fe (Valencia): Marta Montero, José Lacruz, Marino Blanes, Eva Calabuig, Sandra 
Cuellar, José López, Miguel Salavert. Hospital Universitario La Paz/IdiPaz (Madrid): Juan González, 
Ignacio Bernardino de la Serna, José Ramón Arribas, María Luisa Montes, Jose Mª Peña,  Blanca 
Arribas, Juan Miguel Castro, Fco Javier Zamora, Ignacio Pérez, Miriam Estébanez, Silvia García, Marta 
Díaz, Natalia Stella Alcáriz, Jesús Mingorance, Dolores Montero, Alicia González, Maria Isabel de 
José. Hospital de la Princesa (Madrid): Ignacio de los Santos, Jesús Sanz, Ana Salas, Cristina Sarriá, 
Ana Gómez Berrocal, Lucio Garcia-Fraile. Hospital San Pedro-CIBIR (Logroño): José Antonio Oteo, 
José Ramón Blanco, Valvanera Ibarra, Luis Metola, Mercedes Sanz, Laura Pérez-Martínez. Hospital 
Universitario Miguel Servet (Zaragoza): Ascensión Pascual, Carlos Ramos, Piedad Arazo, Desiré Gil. 
Hospital Universitari Mutua de Terrassa (Terrassa): David Dalmau, Angels Jaén, Mireia Cairó, Daniel 
Irigoyen, Queralt Jordano, Mariona Xercavins, Javier Martinez-Lacasa, Pablo Velli, Roser Font, 
Montse Sanmartí, Laura Ibáñez. Complejo Hospitalario de Navarra (Pamplona): María Rivero, Marina 
Itziar Casado, Jorge Alberto Díaz, Javier Uriz, Jesús Repáraz, Carmen Irigoyen, María Jesús Arraiza.  
Hospital Parc Taulí (Sabadell): Ferrán Segura, María José Amengual, Gemma Navarro, Montserrat 
Sala, Manuel Cervantes, Valentín Pineda, Victor Segura, Marta Navarro, Esperanza Antón, Mª Merce 
Nogueras. Hospital Ramón y Cajal (Madrid): Santiago Moreno, José Luis Casado, Fernando Dronda, 
Ana Moreno, María Jesús Pérez Elías, Dolores López, Carolina Gutiérrez, Nadia Madrid, Angel Lamas, 
Paloma Martí, Alberto de Diaz, Sergio Serrrano, Lucas Donat. Hospital Reina Sofía (Murcia): Alfredo 
Cano, Enrique Bernal, Ángeles Muñoz. Hospital San Cecilio (Granada): Federico García, José 
Hernández, Alejandro Peña, Leopoldo Muñoz, Jorge Parra, Marta Alvarez, Natalia Chueca, Vicente 
Guillot, David Vinuesa, Jose Angel Fernández. Centro Sanitario Sandoval (Madrid): Jorge Del Romero, 
Carmen Rodríguez, Teresa Puerta, Juan Carlos Carrió, Mar Vera, Juan Ballesteros. Hospital de la 
Santa Creu i Sant Pau (Barcelona): Pere Domingo, Mª Antonia Sambeat, Karuna Lamarca, Gracia 
Mateo, Mar Gutiérrez, Irene Fernández. Hospital Universitario Santiago de Compostela (Santiago de 
Compostela): Antonio Antela,  Elena Losada. Hospital Son Espases (Palma de Mallorca): Melchor 
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Riera, Maria Peñaranda, Maria Leyes, Mª Angels Ribas, Antoni A Campins, Carmen Vidal, Leire Gil, 
Francisco Fanjul, Carmen Marinescu. Hospital Universitari Vall d´Hebron (Barcelona): Esteban Ribera. 
Hospital Virgen de la Victoria (Málaga): Jesús Santos, Manuel Márquez, Isabel Viciana, Rosario 
Palacios, Isabel Pérez, Carmen Maria González. Hospital Universitario Virgen del Rocío (Sevilla): 
Pompeyo Viciana, Manuel Leal, Luis Fernando López-Cortés, Nuria Espinosa. Hospital Universitario 
de Basurto (Bilbao): Josefa Muñoz, Miren Zuriñe Zubero, Josu Mirena Baraia-Etxaburu, Sofía Ibarra, 
Oscar Ferrero, Josefina López de Munain, Mª Mar Cámara. Iñigo López, Mireia de la Peña. Hospital 
Universitario Infanta Sofía (San Sebastián de los Reyes): Inés Suárez-García, Eduardo Malmierca. 
Hospital Universitario Costa del Sol (Marbella): Julián Olalla, Alfonso del Arco, Javier de la torre, José 
Luis Prada, Zaira Caracuel. Hospital del Poniente (El Ejido): Ana Maria Lopez-Lirola, Ana Belén 
Lozano, Elisa Fernández, Inés Pérez, Juan Manuel Fernández. Hospital Universitario Santa Lucia  
(Cartagena): Onofre Juan Martínez, Francisco Jesús Vera, Lorena Martínez, Josefina García, Begoña 
Alcaraz, Amaya Jimeno. INIBIC-Complejo Hospitalario Universitario de A Coruña (A Coruña): Eva 
Poveda, Berta Pernas, Álvaro Mena, Marta Grandal, Ángeles Castro, José D. Pedreira. Hospital Clínico 
Universitario Virgen de la Arrixaca (Murcia): Carlos Galera, Helena Albendin, Asunción Iborra, 
Antonio Moreno, Maria Angeles Campillo, Asunción Vidal. Hospital Marina Baixa (Villajoyosa): 
Concha Amador, Francisco Pasquau, Javier Ena, Concha Benito, Vicenta Fenoll. Complejo 
Hospitalario de Jaén  (Jaén): Mohamed Omar Mohamed-Balghata, Maria Amparo Gómez. Hospital 
San Agustín de Aviles (Avilés): Miguel Alberto de Zarraga, Maria Eugenia Rivas. Fundación Jiménez 
Diaz (Madrid): Miguel Górgolas. 
 
InfCare HIV, Sweden 
The InfCare HIV cohort is funded by the Swedish Association of Local Authorities and Regions, and by 
the Swedish HIV clinics.  InfCare HIV Steering Committee: Anders Sönnerborg (director), Veronica 
Svedhem-Johansson, Leo Flamholc, Magnus Gisslén, Bo Hejdeman,  Hans Norgren, Suzanne 
Wendahl. InfCare HIV participitating centres: Karolinska University Hospital, South Hospital, 
Sahlgrenska University Hospital, Skane University Hospital, Borås Hospital, Eskilstuna Hospital, Falun 
Hospital, Gävle Hospital, Halmstad Hospital, Helsingborg Hospital, Kalmar Hospital, Karlskrona 
Hospital, Karlstad Hospital, Kristianstad Hospital, Linköping University Hospital, Ryhov County 
Hospital, Skövde Hospital, Sundsvall Hospital, Sunderbyn Hospital, Trollhättan Hospital, Uppsala 
University Hospital, University Hospital of Umeå, Visby Hospital, Västerås Central Hospital, Växjö 
Hospital, Örebro University Hospital, Östersund Hospital.  
 
UK CHIC, UK 
UK CHIC is funded by the UK Medical Research Council (Grant numbers G0000199, G0600337, 
G0900274 and M004236).  The views expressed in this manuscript are those of the researchers and 
not necessarily those of the Medical Research Council.   
UK CHIC Steering Committee: Jonathan Ainsworth, Sris Allan, Jane Anderson, Abdel Babiker, David 
Chadwick, Valerie Delpech, David Dunn, Martin Fisher, Brian Gazzard, Richard Gilson, Mark Gompels, 
Phillip Hay, Teresa Hill, Margaret Johnson, Sophie Jose, Stephen Kegg, Clifford Leen, Fabiola Martin, 
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